Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer
2013 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 108, no 11, 2321-2328 p.Article in journal (Refereed) Published
Background: Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer. Methods: Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n = 100 (Cohort I) and n = 343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed. Results: Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR = 2.25 in Cohort I and 3.10 in Cohort II, adjusted HR = 2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR = 4.36, adjusted HR = 2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR = 6.19, adjusted HR = 4.60) and DSS (unadjusted HR = 8.34, adjusted HR = 7.16). Conclusion: Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.
Place, publisher, year, edition, pages
2013. Vol. 108, no 11, 2321-2328 p.
podocalyxin-like protein, urothelial bladder cancer, prognosis
Cancer and Oncology
IdentifiersURN: urn:nbn:se:kth:diva-136897DOI: 10.1038/bjc.2013.215ISI: 000320249500016ScopusID: 2-s2.0-84884185522OAI: oai:DiVA.org:kth-136897DiVA: diva2:679200
QC 201312132013-12-132013-12-092014-01-22Bibliographically approved